Open-label placebos as adjunctive therapy for patients with depression

Effects of Open-Label Placebos on Visual Food Cue Reactivity in Children and Adolescents

BACKGROUND

A high level of food cue reactivity (FCR) is a risk factor for overeating and weight gain. This randomized trial investigated whether open-label placebos (OLPs: placebos honestly administered) can reduce FCR (reported appetite) in children and adolescents.

METHOD

Children (n = 73; 8-12 years old) and adolescents (n = 187; 16-18 years old) were randomly assigned to either an OLP group or a control group (without OLP). Participants viewed images depicting food (sweets and fruits) and non-food items. Before viewing, the OLP group received a placebo for appetite reduction. Participants rated their desire to eat the depicted food items (0-100) and the perceived effectiveness of the OLP intervention.

RESULTS

The OLP exhibited a large effect in children, leading to a general reduction in appetite (group difference OLP vs. no OLP: M = -20.8; ηp2 = 0.20). This general effect was absent in adolescents, whose appetite reduction was restricted to fruits (OLP vs. no OLP: M = -8.1; ηp2 = 0.03). Additionally, children perceived the OLP as more effective than adolescents.

CONCLUSION

The reduced response and skeptical attitudes of adolescents towards OLP treatment require further investigation.

Effects of (non)deceptive placebos on reported sleep quality and food cue reactivity

A lack of sleep can increase appetite, particularly for high-calorie food. The current study tested the effects of an open-label placebo for improving sleep quality and reducing food cue reactivity. In open-label placebo interventions, placebo recipients are informed that they are receiving a placebo without a pharmacologically active substance. Participants (n = 150) were randomly allocated to one of three groups that received either an open-label placebo to improve sleep quality, a deceptive placebo ("melatonin"), or no placebo. The placebo was administered daily before bedtime for 1 week. Sleep quality and reactivity to high-calorie food cues (appetite, visual attention to food images) were assessed. The deceptive placebo (but not the open-label placebo) reduced reported sleep-onset latency. The open-label placebo decreased perceived sleep efficiency. The placebo interventions did not change food cue reactivity. This study demonstrated that open-label placebos do not present an alternative to deceptive placebos for improving sleep quality. The undesirable open-label placebo effects found warrant further exploration.

Would You Take an Open-Label Placebo Pill or Give One to Your Child? Findings from a Cross-Sectional Survey

Background

Open-label placebos (OLPs), honestly prescribed regarding their inert nature, have been associated with positive health-related effects in both children and adults. However, OLPs are not always perceived by laypeople as a viable treatment option.

Methods

A brief online survey with 806 adult participants (age range: 18-75 years; 29% parents) was conducted to identify predictor variables that are associated with the willingness to take an OLP pill (criterion 1) or to give an OLP to one's child (criterion 2). The survey covered aspects including the perceived plausibility of the treatment concept for both OLPs and deceptive placebos (DPs), self-reported knowledge about placebos, the expected effectiveness of OLPs in treating emotional/ somatic problems, and attitudes concerning taking pills in general. Multiple hierarchical regressions were carried out.

Results

The expected effectiveness of OLPs in alleviating both emotional and physical ailments and the plausibility of the treatment concepts for both OLPs and DPs significantly predicted the willingness to use OLPs (R2 = 0.485). A similar finding was observed when predicting the willingness to administer an OLP to one's child (R2 = 0.443).

Conclusion

Favorable expectations regarding the reduction of emotional and somatic symptoms with OLPs, along with a strong belief in the credibility of placebo mechanisms, play a vital role in influencing the willingness to accept this kind of treatment. These factors can be incorporated into psychoeducational programs.

Study protocol: combined N-of-1 trials to assess open-label placebo treatment for antidepressant discontinuation symptoms [FAB-study]

BACKGROUND

Antidepressant discontinuation is associated with a broad range of adverse effects. Debilitating discontinuation symptoms can impede the discontinuation process and contribute to unnecessary long-term use of antidepressants. Antidepressant trials reveal large placebo effects, indicating a potential use of open-label placebo (OLP) treatment to facilitate the discontinuation process. We aim to determine the effect of OLP treatment in reducing antidepressant discontinuation symptoms using a series of N-of-1 trials.

METHODS

A series of randomized, single-blinded N-of-1 trials will be conducted in 20 patients with fully remitted DSM-V major depressive disorder, experiencing moderate to severe discontinuation symptoms following antidepressant discontinuation. Each N-of-1 trial consists of two cycles, each comprising two-week alternating periods of OLP treatment and of no treatment in a random order, for a total of eight weeks. Our primary outcome will be self-reported discontinuation symptoms rated twice daily via the smartphone application 'StudyU'. Secondary outcomes include expectations about discontinuation symptoms and (depressed) mood. Statistical analyses will be based on a Bayesian multi-level random effects model, reporting posterior estimates of the overall and individual treatment effects.

DISCUSSION

Results of this trial will provide insight into the clinical application of OLP in treating antidepressant discontinuation symptoms, potentially offering a new cost-effective therapeutic tool. This trial will also determine the feasibility and applicability of a series of N-of-1 trials in a clinical discontinuation trial.

TRIAL REGISTRATION

ClinicalTrials.gov: NCT05051995, first registered September 20, 2021.

The impact of pharmaceutical form and simulated side effects in an open-label-placebo RCT for improving psychological distress in highly stressed students

Open-label placebo (OLP) may be utilized to reduce psychological distress. Yet, potential contextual effects have not been explored. We investigated the impact of pharmaceutical form and the simulation of side effects in a parallel group RCT (DRKS00030987). A sample of 177 highly stressed university students at risk of depression were randomly assigned by computer generated tables to a 1-week intervention with active or passive OLP nasal spray or passive OLP capsule or a no-treatment control group. After the intervention, groups differed significantly in depressive symptoms but not regarding other outcomes of psychological distress (stress, anxiety, sleep quality, somatization), well-being or treatment expectation. OLP groups benefitted significantly more compared to the no-treatment control group (d = .40), OLP nasal spray groups significantly more than the OLP capsule group (d = .40) and the active OLP group significantly more than the passive OLP groups (d = .42). Interestingly, before intervention, most participants, regardless of group assignment, believed that the OLP capsule would be most beneficial. The effectiveness of OLP treatments seems to be highly influenced by the symptom focus conveyed by the OLP rationale. Moreover, pharmaceutical form and simulation of side effects may modulate efficacy, while explicit treatment expectation seems to play a minor role.

Placebo effects during the waiting period for psychotherapy in patients with depression

Patients with mental health problems typically have to wait for psychological therapies. This study aimed to investigate the effects of a placebo administered to patients with depression while they were waiting for cognitive-behavioral therapy. Sixty-seven patients were randomly assigned to a three-week waiting period with or without treatment with a take-home placebo for daily usage (herbal medicine to mobilize the body’s natural healing powers to be taken orally). Symptoms of depression (self-rated and clinician-rated) were assessed at the beginning and end of the waiting period. Moreover, each week the patients evaluated levels of energy, concentration, relaxation, well-being, and sleep quality. The placebo group showed a greater reduction in symptoms of depression (self-rated and clinician-rated) compared to the standard group. Moreover, placebo treatment was associated with improved overall well-being during the waiting period. In conclusion, placebo treatment can make the wait time for psychotherapy more tolerable for patients with depression.

Clinical trial registration: German Clinical Trials Register (DRKS00028118)